Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1.
3'-Azido-2',3'-deoxythymidine and carbovir [racemic and (-) enantiomer] were evaluated individually and in combination for antiviral activity against human immunodeficiency virus type 1 replication and cytotoxicity in vitro. The combination of these drugs synergistically inhibited human immunodeficiency virus type 1 replication in C3 and Jurkat cells and in human peripheral blood mononuclear cells, although the same combination also produced synergistic cytotoxicity in human peripheral blood mononuclear cells.
Smith
M S
MS
Lineberger Comprehensive Cancer Research Center, University of North Carolina, Chapel Hill 27599-7295.
Kessler
J A
JA
Rankin
C D
CD
Pagano
J S
JS
Kurtzberg
J
J
Carter
S G
SG
D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D015224:Dideoxynucleosides / Q000494:pharmacology*; D004357:Drug Synergism; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D010948:Viral Plaque Assay; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000494:pharmacology*
D000998:Antiviral Agents; D015224:Dideoxynucleosides; C057503:carbovir; D015215:Zidovudine